8-K: ESSA Pharma Details Shareholder Cash Distribution and Tax Implications Ahead of XenoTherapeutics Merger

ESSA Pharma Inc. has informed shareholders about the potential U.S. and Canadian federal income tax consequences of a planned cash distribution tied to its business combination with XenoTherapeutics, Inc.

Summary

• ESSA Pharma Inc. (the "Company") has mailed a letter to its shareholders detailing the potential U.S. and Canadian federal income tax consequences of an initial cash distribution.
• This distribution is intended to be made in connection with the Company's previously announced business combination agreement with XenoTherapeutics, Inc. ("Xeno").
• The transaction involves Xeno Acquisition Corp., a wholly-owned subsidiary of Xeno, acquiring all issued and outstanding common shares of ESSA Pharma.
• Prior to the closing of the transaction, the Company intends to reduce the capital of its Common Shares and make a concurrent distribution to shareholders as part of the discontinuance and winding-up of its business.
• The distribution is subject to approval by the Supreme Court of British Columbia, with a hearing for the Interim Order and Distribution Order scheduled for August 5, 2025, at 9:45 a.m. Pacific time.
• For U.S. federal income tax purposes, the Company intends to treat the distribution as part of a complete liquidation, generally resulting in capital gain or loss for U.S. Holders.
• The Company believes it was classified as a Passive Foreign Investment Company (PFIC) for the taxable year ending September 30, 2024, and expects to be for the current year, which could lead to adverse tax consequences for U.S. Holders without specific elections (QEF or mark-to-market).
• For Canadian Resident Holders, the distribution is expected to be treated as a tax-free return of capital, reducing the adjusted cost base of shares, with any excess over cost base resulting in a capital gain.
• Canadian Non-Resident Holders may face Canadian withholding tax on any deemed dividends and capital gains tax if shares are considered 'taxable Canadian property' and not exempt by treaty.

Sentiment

Score: 5

Explanation: The filing is neutral in tone, primarily providing factual information about a corporate transaction and its complex tax implications. It highlights potential risks, particularly regarding tax treatment and the PFIC status, but does not present inherently positive or negative operational results.

Positives

• The planned cash distribution to shareholders provides a return of capital as part of the business combination.
• The business combination with XenoTherapeutics, Inc. represents a strategic transaction for the Company.

Negatives

• The Company's classification as a Passive Foreign Investment Company (PFIC) for current and prior taxable years could lead to significant adverse tax consequences for U.S. Holders if certain elections are not made.
• The tax treatment of the distribution, particularly for Canadian Resident Holders, is not entirely free from doubt and relies on a specific exception for winding-up or discontinuance.

Risks

• No assurance can be given that the Company will make the distribution or as to its amount or timing, as it is subject to Court approval.
• The IRS may not agree with the Company's conclusion that the distribution should be treated as one in a series of liquidating distributions, potentially leading to adverse tax consequences for U.S. Holders.
• If the Company is classified as a PFIC, U.S. Holders without a timely QEF or mark-to-market election may recognize gain as ordinary income, allocated ratably over their holding period, and be subject to an interest charge.
• Potential litigation relating to the transaction could be instituted by or against the Company, Xeno, XOMA Royalty Corporation, or their respective directors or officers.
• Disruptions from the transaction could harm the Company's business, including current plans and operations.
• The Company's ability to retain and hire key personnel may be impacted.
• Potential adverse reactions or changes to business relationships could result from the announcement or completion of the transaction.
• Continued availability of capital and financing and rating agency actions are uncertain.
• Legislative, regulatory, and economic developments could affect the Company's business.
• The accuracy of the Company's financial projections is subject to uncertainty.
• General business, market, and economic conditions could impact the transaction.
• Certain restrictions during the pendency of the transaction may impact the Company's ability to pursue business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, outbreaks of war or hostilities, could affect the Company.
• Significant transaction costs are associated with the transaction.
• The transaction may be more expensive to complete than anticipated due to unexpected factors or events.
• Competitive responses to the transaction are possible.
• Unlisted factors may present significant additional obstacles to the realization of forward-looking statements.
• Consequences of material differences in results compared to anticipated outcomes could include business disruption, operational problems, financial loss, legal liability, and impact on financial condition, results of operations, credit rating, or liquidity.

Future Outlook

The Company's future outlook is primarily focused on the successful completion of the business combination with XenoTherapeutics, Inc., the execution of the planned cash distribution to shareholders, and the subsequent winding-up of its current business. The timing and receipt of necessary securityholder, regulatory, and court approvals are key forward-looking elements.

Management Comments

• "As previously announced, on July 13, 2025, ESSA Pharma Inc. (the Company), entered into a Business Combination Agreement (the Agreement) with XenoTherapeutics, Inc., Xeno Acquisition Corp., a wholly-owned subsidiary of Xeno (Purchaser) and XOMA Royalty Corporation, under which Purchaser will acquire all of the issued and outstanding common shares (the Common Shares, and the holders of such Common Shares, the Shareholders) of the Company (the Transaction)."
• "Pursuant to the terms of the Agreement, the Company, once it has obtained an order from the Supreme Court of British Columbia (the Court) authorizing it to do so, intends to reduce the capital of its Common Shares and make a concurrent distribution to Shareholders of an amount equal to the reduction in capital as part of the discontinuance and winding-up of the business of the Company (the Distribution) prior to the closing of the Transaction."
• "The Company is sending this letter to provide you with information regarding the potential U.S. and Canadian federal income tax consequences of the Distribution in advance of an upcoming Shareholder vote regarding the Transaction."
• "As the Distribution is subject to Court approval, no assurance can be given that the Company will make the Distribution or as to the amount or timing of the Distribution, if it is made."
• "The Company believes that it was classified as a PFIC for the taxable year ending September 30, 2024 and in certain prior years, and expects to be classified as a PFIC for the current taxable year."
• "Although not free from doubt, the Company is of the view that this exception should apply to the Distribution."

Industry Context

This announcement relates to a specific corporate transaction, a business combination, and the subsequent winding-up of ESSA Pharma Inc.'s existing business. It reflects a strategic shift for the Company, moving towards a new structure under XenoTherapeutics, Inc. The detailed tax guidance is crucial for shareholders navigating such a significant corporate event, especially given the cross-border nature (U.S. and Canada) and the complexities of PFIC status for U.S. investors.

Corporate Governance

Legal Proceedings

• The Company is making an application to the Supreme Court of British Columbia for an Interim Order and a Distribution Order, with a hearing scheduled for August 5, 2025.
• Potential litigation relating to the transaction could be instituted by or against the Company, XenoTherapeutics, Inc., XOMA Royalty Corporation, or their respective directors or officers.

Stakeholder Impact

• Shareholders: Will receive a cash distribution and face complex U.S. and Canadian federal income tax consequences, particularly concerning PFIC status for U.S. Holders. Their shares will be acquired by Xeno Acquisition Corp.
• Employees: The transaction carries a risk regarding the Company's ability to retain and hire key personnel, implying potential impact on employment.
• XenoTherapeutics, Inc. and XOMA Royalty Corporation: Are key parties in the business combination, with Xeno acquiring ESSA's shares.
• Regulatory Authorities (SEC, CRA): Will be involved in reviewing filings and ensuring compliance with securities and tax laws.

Next Steps

• Shareholder vote regarding the Transaction and Distribution.
• Application to the Supreme Court of British Columbia for an Interim Order and Distribution Order, with a hearing scheduled for August 5, 2025.
• Filing of a Proxy Statement and management information circular with the SEC, which will provide additional information on the transaction and tax considerations.
• Satisfaction of conditions to the completion of the transaction, including securityholder, regulatory, and court approvals.
• Completion of the business combination with XenoTherapeutics, Inc.
• Potential subsequent dissolution and liquidation of ESSA Pharma Inc.'s business.

Key Dates

Recommendation

The filing details a significant corporate transaction involving a business combination, a cash distribution, and the winding-up of the company's current business. While the distribution provides a return of capital, the complex U.S. and Canadian tax implications, particularly the Passive Foreign Investment Company (PFIC) status, introduce uncertainty for shareholders. A 'hold' recommendation is prudent until the full terms of the transaction, the exact distribution amount, and the final tax guidance are clearer, allowing investors to assess the net financial impact and strategic value. The risks associated with court approvals and potential litigation also warrant caution.

Keywords

ESSA Pharma, XenoTherapeutics, Business Combination Agreement, Cash Distribution, SEC Filing, Tax Consequences, U.S. Federal Income Tax, Canadian Federal Income Tax, PFIC, Passive Foreign Investment Company, Liquidation, Capital Reduction, Shareholder Letter, Corporate Transaction, Merger, Winding-up